Hikal Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/w5z9l6xokkb3zxwen6gizwal.pdf

Key Takeaways


Demand Environment & Volume Headwinds

Hiremath: "If you look at historically, our quarter one is always our slowest quarter because we take our annual maintenance shutdowns. And this is a time every year our quarter one is our slowest and we always have a sequential step wise improvement quarter-on-quarter, and this year is no different."

Margin Trajectory & Operating Leverage

Hiremath: "If you look at the pharma business for the new projects and the new products, we're getting closer to the 24%-25% up of EBITDA level, my obviously particular blend because of a legacy for us it may come down to 20% odd as a blended. So, our aim is for any new project, we're targeting 24%-25% EBITDA. And obviously, we'll strive for even better."

Capacity Expansion & New Projects


Regulatory & Operational Updates


Strategic Positioning & Long-Term Bets

Hiremath: "I am not even talking of 10 years, I am talking of next four to five years, we will see a significant uptick in margins, and the operating leverage kicking in as volumes increase."

Guidance & Commitments

CommitmentSpecificsTimeline
Pharma demand normalizationCDMO and API demand returns to normal as channel inventory clearsNext 1-2 quarters (by end-FY24)
Crop inventory normalizationDistributor/end-customer destocking ends, demand and prices normalizeEnd of calendar 2023 / Q3-Q4 FY24
Volume recoveryVolumes pick up, driving operating leverage and EBITDA improvementH2 FY24 onwards
New product launches3-4 new products launched from a pipeline of 8-10 under developmentBy end of FY24
Validation batches (animal health)Validation quantities provided to customer from new dedicated facilityQ3-Q4 FY24
Capacity utilizationUtilization returns from 65-75% to 80-85%H2 FY24
Raw material margin benefitLower-cost inventory flows through to finished goods, improving marginsEnd of Q2 / early Q3 FY24
New project EBITDA marginAll new projects and products contracted at 24-25% EBITDAOngoing (from now)
Blended margin recoveryExisting gross block returns to 18-19% EBITDA; new projects lift blended toward 20%Next 2 years
Panoli GPCB permanent revocationPermanent revocation of closure direction after initial 3-month periodWithin 3 months (by Oct 2023)

Key Metrics

MetricQ1 FY24
Revenue₹388 cr, +2.4% YoY; -29% QoQ
EBITDA₹50 cr
EBITDA margin12.9%
Pharma revenue₹225 cr
Pharma EBIT margin4.4%
Crop protection revenue₹163 cr
Crop protection EBIT margin10.5%
Volume change-13% YoY; -26% QoQ
Pharma capacity utilization70%-75%, vs historical 80%-85%
Crop protection capacity utilizationmid-60s%, vs historical 80%-85%
Term loans₹550 cr
Working capital debt₹240 cr
Cost of funds8.5%, blended short and long term
Capital work-in-progress₹400-460 cr as of June 30, 2023
FY24 capex plan₹200 cr, 50:50 internal accruals and borrowings